gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

CD37 molecule

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This encoded protein is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. It may play a role in T-cell-B-cell interactions. Alternate splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CD19, CD20, CD53, CD63, CD81
Papers using CD37 antibodies
Akt/PKB regulates actin organization and cell motility via Girdin/APE.
Masucci Maria G., In PLoS ONE, 2004
... Technology (Danvers, MA), iNOS antibody was from BD Transduction laboratories (Franklin Lakes, NJ), mouse anti-human CD37 antibody was from BD Biosciences and actin antibody was ...
Papers on CD37
Tetraspanin CD37 protects against the development of B cell lymphoma.
van Spriel et al., In J Clin Invest, Feb 2016
Here, we have provided evidence that deficiency of tetraspanin superfamily member CD37, which is important for B cell function, induces the development of B cell lymphoma.
Dendritic Cell Migration and Antigen Presentation Are Coordinated by the Opposing Functions of the Tetraspanins CD82 and CD37.
Wright et al., Melbourne, Australia. In J Immunol, Feb 2016
UNASSIGNED: This study supports a new concept where the opposing functions of the tetraspanins CD37 and CD82 may coordinate changes in migration and Ag presentation during dendritic cell (DC) activation.
Tetraspanin CD37 Regulates β2 Integrin-Mediated Adhesion and Migration in Neutrophils.
Wright et al., Melbourne, Australia. In J Immunol, Jan 2016
In this study, we investigated the contribution of the tetraspanin CD37 to this key process.
The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.
Sun et al., United States. In Anaerobe, Dec 2015
Clostridium difficile CD37, a clinical isolate from the USA, does not produce toxin A, B or binary toxin.
Down-regulation of CD53 expression in Epinephelus coioides under LPS, Poly (I:C), and cytokine stimulation.
Lin et al., Tainan City, Taiwan. In Fish Shellfish Immunol, Dec 2015
Members of the tetraspanin family include CD9, CD37, CD63, and CD53, and others.
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Forero-Torres et al., Birmingham, United States. In Curr Oncol Rep, Sep 2015
Newer ADCs, such as polatuzumab vedotin (targeting CD79b), pinatuzumab vedotin (targeting CD22), inotuzumab ozogamicin (targeting CD19), SAR3419 (targeting CD19), IMGN529 (targeting CD37), and SGN-CD19A (targeting CD19), have shown promising preclinical and early clinical activity.
Tetraspanins as therapeutic targets in hematological malignancy: a concise review.
Muthusamy et al., Columbus, United States. In Front Physiol, 2014
There are a select few, such as CD37 and CD53, which are restricted to hematopoietic lineages.
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
Robak, Łódź, Poland. In Expert Rev Hematol, 2014
The most promising newer mAbs are directed against CD20, CD19, CD37 and CD40.
Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak et al., Łódź, Poland. In Expert Opin Biol Ther, 2014
More recently, CD37, a member of the tetraspanin superfamily of cell surface antigens, has been considered as a target for B-cell malignancies.
Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.
Khan et al., Bethesda, United States. In Front Oncol, 2013
Of these, only CD52, CD37, and CD98 are currently being targeted clinically.
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
Byrd et al., Columbus, United States. In Cancer Cell, 2012
Identify two tyrosine residues in tetraspanin CD37 directly mediating transduction of survival and apoptotic signals.
SMIP-016 in action: CD37 as a death receptor.
Cambier et al., Denver, United States. In Cancer Cell, 2012
CD37 is a tetraspannin that triggers cell death and is a potential therapeutic target in cancers.
A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity.
Wright et al., Melbourne, Australia. In J Immunol, 2010
In the absence of both CD37 and Tssc6, immune function is further altered when compared with CD37- or Tssc6-deficient transgenic mice, demonstrating a complementary role for these two molecules in cellular immunity.
The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology.
van Spriel et al., Nijmegen, Netherlands. In Am J Pathol, 2010
CD37 protects against glomerular IgA deposition and renal pathology
The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity.
Figdor et al., Nijmegen, Netherlands. In Plos Pathog, 2009
tetraspanin protein CD37 inhibits IgA responses and regulates the anti-fungal immune response.
Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC.
Wright et al., Australia. In Eur J Immunol, 2009
CD37 and CD151 control DC-mediated T-cell activation by two different mechanisms: CD151 regulates co-stimulation whereas CD37 regulates peptide/MHC presentation
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.
Maecker et al., Stanford, United States. In Annu Rev Immunol, 1997
The tetraspanin superfamily (or TM4SF) includes CD81, CD9, CD37, CD53, CD63, CD82, CD151, and an increasing number of additional proteins.
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
Porter et al., Seattle, United States. In N Engl J Med, 1993
We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 and 1F5) and anti-CD37 (MB-1) antibodies labeled with iodine-131 in 43 patients with B-cell lymphoma in relapse.
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Krohn et al., Seattle, United States. In J Clin Oncol, 1989
A fifth patient, whose tumor did not express the CD37 antigen, was treated with 131I-labeled anti-CD20 MoAb 1F5 and achieved a partial response.
share on facebooktweetadd +1mail to friends